Celltrion discovered ZYMFENTRA™ (infliximab-dyyb), the first and only subcutaneous infliximab treatment, designed specifically for individuals suffering from inflammatory bowel disease.
ZYMFENTRA™ is the only FDA-approved maintenance therapy for adults experiencing moderately to severely active ulcerative colitis (UC) and Crohn’s disease (CD) subsequent to receiving intravenous infliximab treatment.
ZYMFENTRA, is a subcutaneous formulation of the biosimilar infliximab. It functions by inhibiting the activity of tumour necrosis factor-alpha (TNF-alpha), a protein that can be excessively generated in response to specific diseases. This excessive TNF-alpha production can trigger the immune system to mistakenly attack healthy tissues within the body.
ZYMFENTRA provides a groundbreaking and efficient treatment avenue, offering individuals with inflammatory bowel disease (IBD) a distinct administration choice that empowers them to manage where and how they receive their treatment.
This underscores the dedication to providing top-notch, cost-effective treatment alternatives that significantly benefit patients and contribute to the efficiency of our healthcare system.
This infliximab biosimilar stands as the world's pioneering monoclonal antibody biosimilar. Its extensive scope includes treatment indications for eight autoimmune diseases, notably addressing conditions such as Crohn’s disease (CD) and ulcerative colitis (UC), offering a versatile therapeutic option for a range of health concerns.
